Patients were safely able to return home and receive the diuretic by minipump, minimizing their time spent at the hospital.
The FDA approved a subcutaneous 24-hour continuous infusion of foscarbidopa and foslevodopa (Vyalev) for advanced Parkinson's disease, AbbVie announced Thursday. Foscarbidopa and foslevodopa are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results